{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:36:14Z","timestamp":1747208174050,"version":"3.40.5"},"reference-count":70,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.2217\/fon-2021-0602","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T08:42:42Z","timestamp":1644482562000},"page":"755-769","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Acalabrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5880","authenticated-orcid":false,"given":"Miklos","family":"Egyed","sequence":"first","affiliation":[{"name":"Department of Hematology,Somogy County Moritz Kaposi General Hospital,\rKaposvar,\rHungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandor","family":"Lueff","sequence":"additional","affiliation":[{"name":"Department of Hematology,Somogy County Moritz Kaposi General Hospital,\rKaposvar,\rHungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Borbely","sequence":"additional","affiliation":[{"name":"AstraZeneca,\rBudapest,\r1116,\rHungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpad","family":"Illes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,University of Debrecen,\rDebrecen,\rHungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48445-1"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1312.1312"},{"issue":"204","key":"e_1_3_3_6_1","first-page":"1","article-title":"BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-na\u00efve elderly patients with CL","volume":"11","author":"Rogers A","year":"2020","unstructured":"Rogers A , JenniferA, WoyachJA. BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-na\u00efve elderly patients with CL. Ther. Adv. Hematol.11(204), 1\u201310 (2020).","journal-title":"Ther. Adv. Hematol."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13077"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0637"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4732"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F"},{"key":"e_1_3_3_13_1","unstructured":"Imbruvica (ibrutinib) [package insert]. Pharmacyclics LLC and Janssen Biotech Inc. (2018)."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-362624"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3575"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107011"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119669"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.12"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1304"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3118.3118"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3504"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124614"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_3_3_27_1","unstructured":"Plieth J . EHA 2019 \u2013 Sunesis chases Arqule but remissions prove elusive (2019). www.evaluate.com\/vantage\/articles\/events\/conferences\/eha-2019-sunesis-chases-arqule-remissions-prove-elusive"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126286"},{"key":"e_1_3_3_29_1","unstructured":"National Library of Medicine . PubChem.https:\/\/pubchem.ncbi.nlm.nih.gov"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"issue":"4","key":"e_1_3_3_31_1","first-page":"298","article-title":"Final results of phase1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach J","year":"2019","unstructured":"Woyach J , StephensD, FlinnIWet al. Final results of phase1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood134(Suppl. 4), 298 (2019).","journal-title":"Blood"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000559028.54436.a5"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2596"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_3_38_1","unstructured":"EMA . Calquence (acalabrutinib) SmPC. www.ema.europa.eu"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0852-8"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2624"},{"issue":"19","key":"e_1_3_3_41_1","article-title":"ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma","volume":"74","author":"Gardner HL","year":"2014","unstructured":"Gardner HL , HarringtonBK, IzumiRet al. ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. Cancer Res.74(Suppl. 19), Abstract 1744 (2014).","journal-title":"Cancer Res."},{"key":"e_1_3_3_42_1","unstructured":"ACP-196 (acalabrutinib) a novel Bruton tyrosine kinase (Btk) inhibitor for treatment of chronic lymphocytic leukemia NCT02029443 (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02029443?term=ACP*196&draw=3&rank=28"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7521"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8024"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.638.638"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7530"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.29_2629"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8015"},{"key":"e_1_3_3_51_1","unstructured":"ClinicalTrials.gov Study of Acalabrutinib (ACP-196) versus ibrutinib in previously treated subjects with high risk CLL (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477696?term=NCT02477696&draw=2&rank=1"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7500"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_3_54_1","unstructured":"ClinicalTrials.gov . Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed\/Refractory or Untreated CLL\/SLL\/PLL (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02296918"},{"key":"e_1_3_3_55_1","first-page":"432","article-title":"Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-na\u0131ve patients with chronic lymphocytic leukemia: the phase 1b\/2 ACE-CL-003 study","volume":"130","author":"Woyach JA","year":"2017","unstructured":"Woyach JA , AwanFT, JianfarMet al. Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-na\u0131ve patients with chronic lymphocytic leukemia: the phase 1b\/2 ACE-CL-003 study. Blood130, 432 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7500"},{"issue":"1","key":"e_1_3_3_57_1","article-title":"Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment-na\u00efve or relapsed\/refractory chronic lymphocytic leukemia","volume":"136","author":"Woyach JA","year":"2020","unstructured":"Woyach JA , BlachlyJS, RogersKAet al. Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment-na\u00efve or relapsed\/refractory chronic lymphocytic leukemia. Blood136(Suppl. 1), 5 November 2020.","journal-title":"Blood"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.26_2630"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127506"},{"key":"e_1_3_3_60_1","volume-title":"62nd ASH Annual Meeting and Exposition.","author":"Davids MS","year":"2020","unstructured":"Davids MS , LampsonBL, TyekuchevaSet al. Updated safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab (AVO) for frontline treatment of chronic lymphocytic leukemia (CLL). 62nd ASH Annual Meeting and Exposition.Virtual Meeting, 5\u20138 December 2020 (Poster 2216)."},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.08.017"},{"key":"e_1_3_3_62_1","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd JC","year":"2017","unstructured":"Byrd JC , OwenR, O'BrienSMet al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood130, 4326 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134797"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136109"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000411"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123057"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003244"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:29Z","timestamp":1719125009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.2217\/fon-2021-0602"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0602","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}